Choline Kinase α Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells
Lung cancer is one of the main causes of death in developed countries, and non-small cell lung cancer (NSCLC) is the most frequent type (80% of patients). In advanced NSCLC, platinum-based chemotherapy is the frontline palliative treatment, but less than 5% of patients achieve prolonged survival. Im...
Saved in:
Main Authors: | Juan Carlos Lacal (Author), Rosario Perona (Author), Javier de Castro (Author), Arancha Cebrián (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Choline Kinase: An Unexpected Journey for a Precision Medicine Strategy in Human Diseases
by: Juan Carlos Lacal, et al.
Published: (2021) -
Parallel Colorimetric Quantification of Choline and Phosphocholine as a Method for Studying Choline Kinase Activity in Complex Mixtures
by: Tahl Zimmerman, et al.
Published: (2018) -
Choline Kinase, A Novel Drug Target for the Inhibition of Streptococcus pneumoniae
by: Tahl Zimmerman, et al.
Published: (2017) -
Anticancer and Structure Activity Relationship of Non-Symmetrical Choline Kinase Inhibitors
by: Santiago Schiaffino-Ortega, et al.
Published: (2021) -
Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines
by: Pablo García-Molina, et al.
Published: (2022)